Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Janumet is a prescription combination of sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin hydrochloride, a biguanide. It is used with diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Current tablets contain 50 mg of sitagliptin with either 500 mg or 1000 mg of metformin hydrochloride.
read more about janumet ...Sitagliptin inhibits DPP-4 and slows breakdown of incretin hormones, which increases glucose-dependent insulin release and reduces glucagon secretion. Metformin lowers hepatic glucose production, reduces intestinal glucose absorption, and improves insulin sensitivity. The two actions lower blood glucose through different pathways.
Janumet is used in adults with type 2 diabetes mellitus as an adjunct to diet and exercise. It is not used for type 1 diabetes. Current labeling states that Janumet has not been studied in patients with a history of pancreatitis.
Janumet is taken twice daily with meals. Patients not currently taking metformin usually start with 50 mg of sitagliptin and 500 mg of metformin twice daily. The maximum daily dose is 100 mg of sitagliptin and 2000 mg of metformin. Kidney function is assessed before treatment and periodically afterward.
Janumet carries a boxed warning for metformin-associated lactic acidosis, which can be fatal. Other serious concerns include pancreatitis, heart failure risk associated with the DPP-4 inhibitor class, acute kidney failure, vitamin B12 deficiency, severe hypersensitivity, severe joint pain, bullous pemphigoid, and low blood glucose when combined with insulin or an insulin secretagogue.
Janumet is used with diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Janumet is taken twice daily with meals.
The maximum daily dose is 100 mg of sitagliptin and 2000 mg of metformin.
Yes. The boxed warning concerns metformin-associated lactic acidosis.
Effect of Initial Combination Therapy With Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, and Metformin on Glycemic Control in Patients With Type 2 Diabetes. https://pubmed.ncbi.nlm.nih.gov/17485570/. Date Accessed October 6, 2026.
Efficacy and Safety of Initial Combination Therapy With Sitagliptin and Metformin in Patients With Type 2 Diabetes: A 54-Week Study. https://pubmed.ncbi.nlm.nih.gov/19232032/. Date Accessed October 6, 2026.
JANUMET (Sitagliptin and Metformin Hydrochloride) Prescribing Information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d19c7ed0-ad5c-426e-b2df-722508f97d67. Date Accessed October 6, 2026.
Metformin: MedlinePlus Drug Information. https://medlineplus.gov/druginfo/meds/a696005.html. Date Accessed October 6, 2026.
Sitagliptin: MedlinePlus Drug Information. https://medlineplus.gov/druginfo/meds/a606023.html. Date Accessed October 6, 2026.